• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Painful Fissures on Both Hands

News
Poll

How much do you know about erythema annulare centrifugum?

The rash on this man's hands and the red scaly lesions on his trunk are consistent with erythema annulare centrifugum (EAC).

Which of the following statements about this condition are true?

A) EAC is thought to represent a reactive process or antigenic “hypersensitivity” reaction.
B) Although often idiopathic, EAC has been associated with dermatophytosis.
C) Other reported associations include infectious agents, chronic diseases, and malignancy.
D) EAC is often self-limited, but can be chronic and relapsing.
E) All of the above are true.
Related Content
RAD 2025: What You May Have Missed

RAD 2025: What You May Have Missed

Sydney Jennings
June 13th 2025
Article

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings
May 7th 2025
Podcast

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD

Sydney Jennings
June 11th 2025
Article

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

Q&A with Mona Shahriari, MD on Cumulative Life Course Impairment of Atopic Dermatitis

Q&A: Cumulative Life Course Impairment of Atopic Dermatitis with Mona Shahriari, MD

Mona Shahriari, MD;Grace Halsey
June 10th 2025
Article

RAD 2025: As expert dermatologist Shahriari explains it, eczema may be just another rash on your schedule but for a patient, it could be the reason they don't leave the house.

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

Upadacitinib Shows Real-World Efficacy in Bio-Naïve, Bio-Experienced Adults with Atopic Dermatitis in New Study

Sydney Jennings
June 9th 2025
Article

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.

/Gil Yosipovitch, MD Courtesy of Miller School of Medicine

Q&A: Managing Chronic Itch With Renowned Investigator Gil Yosipovitch, MD

Gil Yosipovitch, MD;Grace Halsey
June 9th 2025
Article

RAD 2025: World expert on the pathophysiology of itch Gil Yosipovitch, MD, answers questions on the disease of chronic itch and on the expanding options for targeted treatment.

© 2025 MJH Life Sciences

All rights reserved.